Why November 14 Could Break Summit Therapeutics - A Tactical Short Ahead of the FDA Vote
Summit Therapeutics (SMMT) is trading like a growth oncology story priced for approval. With an FDA decision on ivonescimab expected 11/14/2026, the stock faces a binary outcome: a re-rating on approval or a sharp derating on rejection or label limitations. This trade idea outlines a tactical short designed to capture the asymmetric downside into t…